NEW YORK--(BUSINESS WIRE)--Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Akari Therapeutics, Plc (“Akari” or the “Company”) (NASDAQ:AKTX).
The investigation focuses on whether the Company and its executives violated federal securities laws. Specifically, on May 11, 2017, Akari filed a Form 6-K with the Securities and Exchange Commission announcing that Akari has established an ad hoc special committee to review the involvement of Company personnel regarding a report issued on April 26, 2017 by Edison Investment Research Inc., an investment research and advisory company. Furthermore, the Form 6-K disclosed that Dr. Gur Roshwalb, the Company’s Chief Executive Officer, has been placed on administrative leave while the review is pending.
As a result, the price of Akari’s American Depositary Receipts (“ADRs”) declined significantly, causing harm to investors.
If you invested in Akari ADRs and would like to discuss your legal rights, click here: www.faruqilaw.com/AKTX. There is no cost or obligation to you.
You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to firstname.lastname@example.org.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.